Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks
在Zacks上打开
Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended September 2026, Biogen Inc. (BIIB) reported revenue of $2.8 billion, up 10.6% over the same period last year. EPS came in at $2.62, compared to $4.81 in the year-ago quarter.

The reported revenue represents a surprise of +8.06% over the Zacks Consensus Estimate of $2.59 billion. With the consensus EPS estimate being $2.06, the EPS surprise was +27.18%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Product- Rare Disease- SPINRAZA- United States: $246.4 million compared to the $165.03 million average estimate based on nine analysts. The reported number represents a change of +60.8% year over year. Revenue- Product- Multiple Sclerosis (MS)- Interferon- Rest of world: $75 million compared to the $75.42 million average estimate based on eight analysts. The reported number represents a change of -12.5% year over year. Revenue- Product- Multiple Sclerosis (MS)- Interferon- United States: $133.2 million compared to the $145.98 million average estimate based on eight analysts. The reported number represents a change of -17.4% year over year. Revenue- Product- Rare Disease- SPINRAZA- Rest of World: $214.2 million compared to the $215.49 million average estimate based on eight analysts. The reported number represents a change of -3% year over year. Revenue- Anti-CD20 therapeutic programs: $497.3 million compared to the $497.05 million average estimate based on 11 analysts. The reported number represents a change of +0.7% year over year. Revenue- Contract manufacturing, royalty and other revenue: $149.7 million versus $121.49 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -1% change. Revenue- Product- Multiple Sclerosis (MS)- Interferon- Total: $208.2 million versus $221.55 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -15.7% change. Revenue- Product- Rare Disease- SPINRAZA- Total: $460.6 million compared to the $382.54 million average estimate based on nine analysts. The reported number represents a change of +23.2% year over year. Alzheimer's collaboration revenue: $68.4 million compared to the $69.34 million average estimate based on nine analysts. The reported number represents a change of +60.2% year over year. Revenue- Product- Biosimilars- BENEPALI- Total: $117.3 million compared to the $108.95 million average estimate based on eight analysts. The reported number represents a change of -3.8% year over year. Revenue- Product- Other- ZURZUVAE- Total: $84.4 million versus the eight-analyst average estimate of $76.39 million. The reported number represents a year-over-year change of +52.6%. Revenue- Product- Rare Disease- SKYCLARYS- Total: $178.2 million versus the eight-analyst average estimate of $166.93 million. The reported number represents a year-over-year change of +34.1%.

View all Key Company Metrics for Biogen here>>>

Shares of Biogen have returned +11.3% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Biogen Inc. (BIIB): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research